The Clinical Trials Office (CTO) Shared Resource has as its mission the support of clinical trials by Yale Cancer Center members. This Shared Resource, coupled with the staff of the Protocol Specific Research Support (PSRS) Shared Resource [also referred to as the Clinical Trials Institutional Research Core (CTIRC)] and the Clinical Protocol Review and Monitoring System (CPRMS) Shared Resource, provides the nursing, data management, protocol development expertise, regulatory guidance and patient access needed to successfully conduct Phase I, II and III studies. The long term goal of this Shared Resource is to make it possible for Yale investigators to conduct innovative trials rapidly, in accord with good clinical practice guidelines, with accurate data collection and data available on line in a user friendly data base. This data base has been creative in collaboration with the Center for Medical Informatics and has been adopted by the Medical School as the standard for clinical trials in all area. In the past two years a new clinical trials programs has been added, the Yale Oncology Network (YON), under the direction of the Associate Director for Clinical Trials. YON represents a consortium of hospitals and practices in the State of Connecticut whose purpose is to conduct state of the art clinical trials in the community setting. The CTO plays a critical role in the functionality of the YON by providing administrative and technical support. The focus of this Shared Resource will be Phase I and II studies, especially those which evaluate critical scientific hypotheses, evaluate novel therapies and test promising new agents up through and including studies of proof of concept. The program will continue to evaluate traditional cytotoxics, biologicals as well as new classes of agents.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016359-24
Application #
6101785
Study Section
Project Start
1998-09-23
Project End
1999-06-30
Budget Start
Budget End
Support Year
24
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131
Zhang, Jinhua; Song, Kun; Wang, Jun et al. (2018) S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. Oncoimmunology 7:e1296996
Kelada, Olivia J; Decker, Roy H; Nath, Sameer K et al. (2018) High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. Int J Radiat Oncol Biol Phys 102:174-183
Powles, Ryan L; Redmond, David; Sotiriou, Christos et al. (2018) Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 4:e181564
Wang, Shi-Yi; Hsu, Sylvia H; Huang, Siwan et al. (2018) Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End-of-Life Care. Health Serv Res 53:4291-4309
Gettinger, S N; Choi, J; Mani, N et al. (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196
Liu, Huafeng; Li, Xin; Hu, Li et al. (2018) A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol 15:838-845
Altwerger, Gary; Bonazzoli, Elena; Bellone, Stefania et al. (2018) In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. Mol Cancer Ther 17:1003-1011
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083

Showing the most recent 10 out of 675 publications